Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is 1.3x normal with puts leading calls 8:5. Implied volatility suggests the market is anticipating a move near 17.7%, or $1.55, after ...
SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals (CRVS), Inc. , a clinical-stage biopharmaceutical company, today announced that the company will host a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback